41![Microsoft Word - NOMU0855_NDA[removed]Myfortic - PML DHCP letter 13May08_clean_V2.doc Microsoft Word - NOMU0855_NDA[removed]Myfortic - PML DHCP letter 13May08_clean_V2.doc](https://www.pdfsearch.io/img/25c13019590123283735a0f33908180f.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
42![Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: In Vitro diagnostic devices for JCV antibody detection Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: In Vitro diagnostic devices for JCV antibody detection](https://www.pdfsearch.io/img/b818300a377bd06adbc00076dd8a0f26.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
43![510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K112394 B. Purpose for Submission: 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K112394 B. Purpose for Submission:](https://www.pdfsearch.io/img/76e9c49133d130e4fbc41a70acfcae94.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2012-01-27 15:10:15
|
---|
44![Latest advice for medicines users The monthly newsletter from the Medicines and Healthcare products Regulatory Agency and its independent advisor the Commission on Human Medicines Volume 4, Issue 8, March[removed]Contents Latest advice for medicines users The monthly newsletter from the Medicines and Healthcare products Regulatory Agency and its independent advisor the Commission on Human Medicines Volume 4, Issue 8, March[removed]Contents](https://www.pdfsearch.io/img/ed981e5f4bb37b6689f75ac8a119a2e8.jpg) | Add to Reading ListSource URL: www.mhra.gov.ukLanguage: English - Date: 2011-12-12 06:50:27
|
---|
45![Microsoft Word - Master USPI_Rituxan.doc Microsoft Word - Master USPI_Rituxan.doc](https://www.pdfsearch.io/img/67728cae339ec3e98a22a792b22c5191.jpg) | Add to Reading ListSource URL: www.gene.comLanguage: English - Date: 2014-03-31 07:24:10
|
---|
46![October 2009 IMPORTANT DRUG WARNING Regarding RITUXAN® (Rituximab) Dear Healthcare Professional: Genentech, Inc. and Biogen Idec, Inc. would like to inform you of important new safety information regarding Rituxan (ritu October 2009 IMPORTANT DRUG WARNING Regarding RITUXAN® (Rituximab) Dear Healthcare Professional: Genentech, Inc. and Biogen Idec, Inc. would like to inform you of important new safety information regarding Rituxan (ritu](https://www.pdfsearch.io/img/c73e4610968478f92f81acc7b6f602ed.jpg) | Add to Reading ListSource URL: www.gene.comLanguage: English - Date: 2014-03-31 07:24:11
|
---|
47![MEDICATION GUIDE TYSABRI® (tie-SA-bree) (natalizumab) injection, for intravenous use Read this Medication Guide before you start receiving TYSABRI and before you receive each dose. There may be new information. This Med MEDICATION GUIDE TYSABRI® (tie-SA-bree) (natalizumab) injection, for intravenous use Read this Medication Guide before you start receiving TYSABRI and before you receive each dose. There may be new information. This Med](https://www.pdfsearch.io/img/1157863b560d50ec6ed80985ace4ff04.jpg) | Add to Reading ListSource URL: www.tysabri.comLanguage: English - Date: 2013-12-17 18:23:06
|
---|
48![Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy](https://www.pdfsearch.io/img/3daa96b01dc7e8e142e601fc8a38ac08.jpg) | Add to Reading ListSource URL: www.ncbi.nlm.nih.govLanguage: English |
---|
49![The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study](https://www.pdfsearch.io/img/9e40a8aa4132d6555154a95f434be19a.jpg) | Add to Reading ListSource URL: www.ncbi.nlm.nih.govLanguage: English |
---|